Figure 1
Figure 1. Analysis of endogenous monocyte migration to the dermis and PO-LNs during Leishmania major infection. (A) Diagram of monocyte recruitment and differentiation during Leishmania major infection. (B) Identification of dermal and PO-LN monocytes and mo-DCs at week 3 after infection. 1 indicates monocytes; 2, dermal mo-DCs in the dermis (2a) and after migration to the PO-LNs (2b); 3, LN mo-DCs. (C) Experimental model for the analysis of endogenous monocyte migration. (D-G) Effect of treatment (200 μg/injection) with mAbs anti–PSGL-1 (clone 4RA10), P-selectin (clone RB40.34), E-selectin (clone UZ4), PNAd (clone MECA 79), and/or L-selectin (clone MEL-14) on the absolute number of endogenous monocytes in the dermis (D), monocytes in the PO-LNs (E), dermal mo-DCs after migration to the PO-LNs (F), and LN mo-DCs (G). Data are representative of 4 independent experiments with similar results. (H) Cryostat sections of the dermis and PO-LNs of Leishmania major–infected mice at 4 weeks after infection, after intravenous injection of Alexa-594–conjugated anti-PNAd mAbs (clone MECA-79).

Analysis of endogenous monocyte migration to the dermis and PO-LNs during Leishmania major infection. (A) Diagram of monocyte recruitment and differentiation during Leishmania major infection. (B) Identification of dermal and PO-LN monocytes and mo-DCs at week 3 after infection. 1 indicates monocytes; 2, dermal mo-DCs in the dermis (2a) and after migration to the PO-LNs (2b); 3, LN mo-DCs. (C) Experimental model for the analysis of endogenous monocyte migration. (D-G) Effect of treatment (200 μg/injection) with mAbs anti–PSGL-1 (clone 4RA10), P-selectin (clone RB40.34), E-selectin (clone UZ4), PNAd (clone MECA 79), and/or L-selectin (clone MEL-14) on the absolute number of endogenous monocytes in the dermis (D), monocytes in the PO-LNs (E), dermal mo-DCs after migration to the PO-LNs (F), and LN mo-DCs (G). Data are representative of 4 independent experiments with similar results. (H) Cryostat sections of the dermis and PO-LNs of Leishmania major–infected mice at 4 weeks after infection, after intravenous injection of Alexa-594–conjugated anti-PNAd mAbs (clone MECA-79).

Close Modal

or Create an Account

Close Modal
Close Modal